Chinese Chip Central Planning Creates “Stunning Absurdities That Defy Logic and Common Sense”

(p. B1) Liu Fengfeng had more than a decade under his belt at one of the world’s most prominent technology companies before he realized where the real gold rush in China was taking place.

Computer chips are the brains and souls of all the electronics the country’s factories crank out. Yet they are mostly designed and produced overseas. China’s government is lavishing money upon anyone who can help change that.

. . .

(p. B2) In a way, China is hoping to achieve the same kind of liftoff that helped it progress from making plastic toys to crafting solar panels.

With semiconductors, though, “the model starts to break down a little bit,” said Jay Goldberg, a tech industry consultant and former Qualcomm executive. The technology is eye-wateringly expensive to develop, and established players have spent decades accumulating know-how. Europe, Mr. Goldberg noted, once had many “incredible” chip companies. Japan’s chip makers are leaders in certain specialized products, but few would call them bold innovators.

“My point is, there is a ladder — China’s moving up it,” Mr. Goldberg said. But it’s “unclear which outcome they go to.”

. . .

At a top-level meeting on the economy last week, the Communist Party’s leaders enshrined technological self-reliance as one of the country’s “Five Fundamentals” for economic development.

Complete self-sufficiency in chips, however, would mean recreating every part of the lengthy supply chains for some of the most complex technology on earth — a mission that would seem to lead, if not to madness, at least to waste.

. . .

“Up until very recently — this year — the goal had been: With state backing, move up the value chain, specialize where China has a comparative advantage, but don’t really try and fall down the rabbit hole of trying to build everything yourself,” said Jimmy Goodrich, the vice president for global policy at the Semiconductor Industry Association, a group that represents American chip companies.

Now, “it’s very clear that Xi Jinping is calling for a redundant domestic supply chain,” Mr. Goodrich said. “And so the rules of economics, comparative advantage and the supply-chain efficiencies have basically been thrown out the door.”

The government is conscious of the dangers. State-run news outlets have amply covered the recent semiconductor flameouts. The message to other upstarts: Don’t mess it up.

When the state broadcaster China Central Television visited one stalled project in the eastern city of Huai’an recently, it found dozens of giant machines idling on the factory floor, many of them still sheathed in plastic.

“There have been some stunning absurdities that defy logic and common sense,” China Economic Weekly said.

. . .

“There is definitely a bubble in China,” he said. “But you can’t overgeneralize.”

. . .

“Something is bound to accumulate, whether it’s equipment, talent or factories, right?” Mr. Liu said. “If not you or the other guy, then it will be someone else who ends up using it. I think this might be the government’s logic.”

For the full story, see:

Raymond Zhong and Cao Li. “China’s Frenzy to Master Chip Manufacturing.” The New York Times (Monday, December 28, 2020): B1-B2.

(Note: ellipses added.)

(Note: the online version of the story has the date Dec. 24, 2020, and has the title “With Money, and Waste, China Fights for Chip Independence.”)

Differences in Study Results Are Seldom Due to Whether Study Design Is Observational or a Randomized Clinical Trial

(p. A17) The health system would be less burdened if more patients were treated before they require hospitalization, and there are promising therapeutic options that patients can administer themselves at home. This was the subject of a Nov. 19 [2020] hearing before the Senate Homeland Security and Governmental Affairs Committee.

Testimony from the hearing underscored an important issue: Too many doctors have interpreted the term “evidence-based medicine” to mean that the evidence for a treatment must be certain and definitive before it can be given to patients. Because accusing a physician of not being “evidence based” can be a career-damaging allegation, fear of straying from the pack has prevailed, favoring inertia and inaction amid uncertainty about Covid-19 treatments.

For diseases with established treatment options, holding out for certainty may be prudent. But when options are limited and there are safe treatments with evidence for effectiveness, holding out for certainty can be catastrophic. Requiring a high degree of certainty during a crisis may elevate the augustness of medical organizations and appease the sensibilities of medical professionals, but it does nothing for patients who need help.

The penchant for certainty is visible in the frequently updated treatment guidelines for Covid-19 from the National Institutes of Health. These guidelines were developed by scientists around the country, but because of a mentality that is biased toward virtually irrefutable evidence, no distinction is made for treatments with evidence for effectiveness that falls below the mark of certainty. This framework almost certainly has contributed to many avoidable deaths during this pandemic.

. . .

While some health officials dismiss nonrandomized studies, the Cochrane organization, an international leader in evidence-based medicine, published a review of several hundred studies showing that randomized clinical trials and nonrandomized studies of treatments generally yield similar findings. Modern epidemiologic and statistical methods can usually overcome biases inherent in nonrandomized study designs.

For the full commentary, see:

Joseph A. Ladapo. “Too Much Caution Is Killing Covid Patients.” The Wall Street Journal (Wednesday, Nov. 25, 2020): A17.

(Note: ellipsis, and bracketed year, added.)

(Note: the online version of the commentary has the date November 24, 2020, and has the same title as the print version.)

The Cochrane organization review mentioned above is:

Anglemyer, Andrew, Hacsi T. Horvath, and Lisa Bero. “Healthcare Outcomes Assessed with Observational Study Designs Compared with Those Assessed in Randomized Trials.” In Cochrane Database of Systematic Reviews, 2014.

“A Public Choice Analysis of Mandated Randomized Double-Blind Clinical Trials”

My “A Public Choice Analysis of Mandated Randomized Double-Blind Clinical Trials” was presented on April 13, 2021 in the Law & Economics session of the Association of Private Enterprise Education meetings. I am grateful to Ray DeGennaro and Matthew McClanahan for including me in McClanahan’s session and to Lauren Nicole Hughes for recording the session on her smartphone.

To some extent, the presentation was an outgrowth of my book:

Diamond, Arthur M., Jr. Openness to Creative Destruction: Sustaining Innovative Dynamism. New York: Oxford University Press, 2019.

Pfizer Refused Federal Subsidy so They Could “Liberate” Their “Scientists From Any Bureaucracy”

In September [2020], the CEO of Pfizer, Albert Bourla, appeared on CBS News’s “Face the Nation,” where he was asked about not accepting government funding for development.

“The reason why I did it was because I wanted to liberate our scientists from any bureaucracy,” Bourla explained. “When you get money from someone that always comes with strings. They want to see how we are going to progress, what type of moves you are going to do. They want reports. I didn’t want to have any of that. I wanted them — basically I gave them an open checkbook so that they can worry only about scientific challenges, not anything else.”

“And also,” he added, “I wanted to keep Pfizer out of politics, by the way.”

For the full story, see:

Philip Bump. “No, Pfizer’s Apparent Vaccine Success Is Not a Function of Trump’s ‘Operation Warp Speed.” The Washington Post (online posted Monday, November 9, 2020).

(Note: bracketed year added.)

Unintended Consequences of Centralized Lockdown in India Spread Covid-19

(p. A1) SURAT, India — The crowds surged through the gates, fought their way up the stairs of the 160-year-old station, poured across the platforms and engulfed the trains.

It was May 5 [2020], around 10 a.m. Surat was beastly hot, 106 degrees. Thousands of migrant laborers were frantic to leave — loom operators, diamond polishers, mechanics, truck drivers, cooks, cleaners, the backbone of Surat’s economy. Two of them were Rabindra and Prafulla Behera, brothers and textile workers, who had arrived in Surat a decade ago in search of opportunity and were now fleeing disease and death.

. . .

They were among tens of millions of migrant workers stranded without work or food after Prime Minister Narendra Modi imposed a national coronavirus lockdown in March. By spring and summer, these workers were so desperate that the government provided emergency trains to carry them back to their home villages. The trains were called Shramik Specials, because shramik means “laborer” in Hindi.

But they became the virus trains.

India has now reported more coronavirus cases than any country besides the United States. And it has become clear that the special trains operated by the government to ease suffering — and to counteract a disastrous lack of lockdown planning — instead played a significant role in spreading the coronavirus into almost every corner of the country.

The trains became contagion zones: Every passenger was supposed to be screened for Covid-19 before boarding but few if any were tested. Social distancing, if promised, was nonexistent, as men pressed into passenger cars for journeys that could last days. Then the trains disgorged passengers into distant villages, in regions that before had few if any coronavirus cases.

. . .

(p. A12) On March 24 [2020], at 8 p.m., Mr. Modi hit the lockdown switch. In a televised address, he ordered the entire nation to stay inside their homes for three weeks — starting in four hours.

The decision was pure Modi: sudden, dramatic and firm, like when he abruptly wiped out nearly 90 percent of India’s currency bills in 2016, a bolt-from-the-blue measure that he said was necessary to fight corruption but proved economically devastating.

Prafulla and Rabindra Behera had just finished a dinner of rice, lentils and potatoes, their usual fare. They lived in squalid, bare rooms in Surat’s industrial zone, sleeping wall to wall on the floor with a half dozen other laborers. Within minutes of Mr. Modi’s address, they started getting calls.

“Everyone was thinking the same: This will be over soon and somehow we’ll pass the days,” Rabindra said.

At the time, India had fewer than 600 known virus cases.

Many experts have criticized Mr. Modi’s government for overlooking the plight of migrant laborers, who suddenly had no work, no income and no support network in the cities. The government’s Covid-19 task force lacked migrant specialists and was hardly representative of India. Of its 21 members, only two were women and the rest were largely upper-caste men. Many of the migrant laborers came from lower castes and economically underprivileged backgrounds.

. . .

In Surat, the Behera brothers were down to their last bag of rice. They could not work — the factories were closed. But they weren’t allowed to leave the city, where virus cases were beginning to surge.

“We were trapped,” Rabindra said.

On May 1, India’s Labor Day, the railways ministry made a grand announcement: Shramik Specials. Routes were drawn up from Surat, Mumbai, Chennai, New Delhi, Ahmedabad and other cities deep into rural areas.

. . .

The Beheras were told they would quarantine for 21 days at a center and each was given a toothbrush, a slice of soap, a bucket to wash with and a thin sheet to sleep on.

But the next morning, Prafulla awoke with a splitting headache. A doctor didn’t think he had coronavirus but suggested, as a precaution, that he be moved into the courtyard, away from the other men.

The following morning, Prafulla could barely breathe and called his wife on his cellphone.

“Come and bring the girls,” he whispered. “I need to see you.”

An hour later, he was dead. A subsequent test revealed that Prafulla Behera was Ganjam’s first coronavirus death.

For the full story, see:

Jeffrey Gettleman, Suhasini Raj, Sameer Yasir, Karan Deep Singh and Atul Loke. “Rails Spread Virus as Workers Fled India’s Cities.” The New York Times (Wednesday, December 16, 2020): A1 & A12-A13.

(Note: ellipses added.)

(Note: the online version of the story was updated Feb. [sic] 2, 2021, and has the title “The Virus Trains: How Lockdown Chaos Spread Covid-19 Across India.”)

In the Early Fight Against COVID-19 in China “Front-Line Bureaucrats Were Consumed With Paperwork”

(p. A15) After Chinese leader Xi Jinping ordered rural poverty eliminated by 2020, bureaucrats in the southwestern city of Mianyang got busy—with paperwork.

Instructed to devote 70% of their time to the campaign, they diligently filled out forms certifying compliance, a practice known as “leaving marks,” said Pang Jia, a local judicial clerk who joined the effort. When higher-ups demanded photographic proof of their home visits, some aid workers made up for missing winter photos by posing in cold-weather clothing during summer house calls, Ms. Pang said.

Since taking power in late 2012, Mr. Xi has realigned Chinese politics with his domineering style and a top-down drive to forge a centralized state under the Communist Party. But his efforts are running into an old foe: bureaucracy.

Party observers say the drive for centralization in a sprawling nation too often fosters bureaucratic inertia, duplicity and other(p. A10)unproductive practices that are aimed at satisfying Beijing and protecting careers but threaten to undermine Mr. Xi’s goals.

Indeed, some local officials have become so focused on pleasing Mr. Xi and fulfilling party mandates that they can neglect their basic duties as public servants, sometimes with dire results.

As the new coronavirus spread in Wuhan in late 2019, for instance, local authorities were afraid to share bad news with Beijing. That impeded the national response and contributed to the death toll, according to a Wall Street Journal investigation.

Mr. Xi and other senior officials publicly lamented how front-line bureaucrats were consumed with paperwork instead of fighting the contagion. Officials dedicated hours each day to filling out multiple documents for agencies making overlapping requests for information, including residents’ body temperatures and symptoms.

For the full story, see:

Chun Han Wong. “Xi Jinping’s Eager Minions Snarl His China Plans.” The Wall Street Journal (Monday, March 8, 2021): A15.

(Note: the online version of the story has the date March 7, 2021, and has the title “Xi Jinping’s Eager-to-Please Bureaucrats Snarl His China Plans.”)

Only Very Few of Those Vaccinated Get Covid-19, and When They Do, Symptoms Are Mild or Absent

(p. A8) Nearly 83 million Americans have received at least one dose of a Covid vaccine, and it’s unclear just how many of them will have a “breakthrough” infection, though two new reports suggest the number is very small.

One study found that just four out of 8,121 fully vaccinated employees at the University of Texas Southwestern Medical Center in Dallas became infected. The other found that only seven out of 14,990 workers at UC San Diego Health and the David Geffen School of Medicine at the University of California, Los Angeles tested positive two or more weeks after receiving a second dose of either the Pfizer-BioNTech or Moderna vaccines. Both reports, published on Tuesday [March 23, 2021] in the New England Journal of Medicine, show how well the vaccines work in the real world, and during a period of intense transmission.

. . .

Only some of the virus-positive health workers in the California study showed symptoms, . . ., and they tended to be mild, suggesting that the vaccines were protective. That echoes data from the vaccine trials indicating that breakthrough infections were mild and did not require hospitalizations. Some people had no symptoms at all, and were discovered only through testing in studies or as part of their medical care.

For the full commentary, see:

Denise Grady. “The Vaccinated Can Get Covid, but the Odds are Slim.” The New York Times (Wednesday, March 24, 2021): A8.

(Note: ellipses, and bracketed date, added.)

(Note: the online version of the commentary has the date March 23, 2021, and has the title “Vaccinated People Can Get Covid, but It’s Most Likely Very Rare.”)

The study discussed above is:

Sacerdote, Bruce, Ranjan Sehgal, and Molly Cook. “Why Is All Covid-19 News Bad News?” National Bureau of Economic Research, NBER Working Paper #28110, Nov. 2020.

The NEJM articles mentioned above are:

Daniel, William, Marc Nivet, John Warner, and Daniel K. Podolsky. “Early Evidence of the Effect of Sars-Cov-2 Vaccine at One Medical Center.” New England Journal of Medicine (March 23, 2021).

Keehner, Jocelyn, Lucy E. Horton, Michael A. Pfeffer, Christopher A. Longhurst, Robert T. Schooley, Judith S. Currier, Shira R. Abeles, and Francesca J. Torriani. “Sars-Cov-2 Infection after Vaccination in Health Care Workers in California.” New England Journal of Medicine (March 23, 2021).

Vaccine Immunity, Plus Natural Immunity from Getting Covid-19, Equals Herd Immunity Soon

The author of the passages I quote below is a surgeon and professor at the Johns Hopkins School of Medicine and has authored The Price We Pay, which I recently read. It is a disturbing, eye-opening, excellent account of why the costs of drugs are high and rising.

(p. A17) Anthony Fauci has been saying that the country needs to vaccinate 70% to 85% of the population to reach herd immunity from Covid-19. But he inexplicably ignores natural immunity. If you account for previous infections, herd immunity is likely close at hand.

. . .

Dr. Fauci’s vaccination-only path to herd immunity has significantly influenced the national conversation. KNBC-TV in Los Angeles has a county-by-county vaccine tracker showing a bar graph of the percentage of Californians vaccinated, with the zone 70% to 85% labeled “herd immunity.” Currently, it’s at 26%. The false construct does create a greater urgency for everyone to get vaccinated. But it also creates false justification for continued excessive restrictions on freedom. And it raises the possibility that authorities are misallocating the limited vaccine supply by failing to direct it toward people without natural antibodies.

. . .

Some experts claim they don’t talk about natural immunity because we shouldn’t trust it. But a recent Public Health England study found that less than 1% of 6,614 healthcare workers who had Covid-19 developed a reinfection within five months—even though many of them work with Covid patients. Other experts believe natural immunity is powerful. “Natural immunity after Covid-19 infection is likely lifelong, extrapolating from data on other coronaviruses that cause severe illness, SARS and MERS,” says Monica Gandhi, an infectious-disease physician and professor at the University of California.

For the full commentary, see:

Marty Makary. “Herd Immunity Is Near, Despite Fauci’s Denial.” The Wall Street Journal (Thursday, March 25, 2021): A17.

(Note: ellipses added.)

(Note: the online version of the commentary has the date March 24, 2021, and has the same title as the print version.)

The Makary book praised above is:

Makary, Marty. The Price We Pay: What Broke American Health Care–and How to Fix It. New York: Bloomsbury Publishing, 2019.

U.S. Media Covid-19 Stories More Negative than World Media Stories and than Scientific Journal Stories

(p. A8) Bruce Sacerdote, an economics professor at Dartmouth College, noticed something last year about the Covid-19 television coverage that he was watching on CNN and PBS. It almost always seemed negative, regardless of what was he seeing in the data or hearing from scientists he knew.

When Covid cases were rising in the U.S., the news coverage emphasized the increase. When cases were falling, the coverage instead focused on those places where cases were rising. And when vaccine research began showing positive results, the coverage downplayed it, as far as Sacerdote could tell.

But he was not sure whether his perception was correct. To check, he began working with two other researchers, building a database of Covid coverage from every major network, CNN, Fox News, Politico, The New York Times and hundreds of other sources, in the U.S. and overseas. The researchers then analyzed it with a social-science technique that classifies language as positive, neutral or negative.

The results showed that Sacerdote’s instinct had been right — and not just because the pandemic has been mostly a grim story.

The coverage by U.S. publications with a national audience has been much more negative than coverage by any other source that the researchers analyzed, including scientific journals, major international publications and regional U.S. media. “The most well-read U.S. media are outliers in terms of their negativity,” Molly Cook, a co-author of the study, told me.

About 87 percent of Covid coverage in national U.S. media last year was negative. The share was 51 percent in international media, 53 percent in U.S. regional media and 64 percent in scientific journals.

For the full commentary, see:

David Leonhardt. “The Pandemic Is a Grim Story, but is Bad news the Only Kind?” The New York Times (Wednesday, March 24, 2021): A8.

(Note: the online version of the commentary has the same date as the print version, and has the title “Bad News Bias.”)

The study discussed above is:

Sacerdote, Bruce, Ranjan Sehgal, and Molly Cook. “Why Is All Covid-19 News Bad News?” National Bureau of Economic Research, NBER Working Paper #28110, Nov. 2020.

Distinguished French Scientists Spearhead International Effort to Investigate Possible Wuhan Lab Origin of Covid-19

(p. A8) BEIJING—A World Health Organization team investigating the origins of Covid-19 is planning to scrap an interim report on its recent mission to China amid mounting tensions between Beijing and Washington over the investigation and an appeal from one international group of scientists for a new probe.

The group of two dozen scientists is calling in an open letter on Thursday [March 4,2021] for a new international inquiry. They say the WHO team that last month completed a mission to Wuhan—the Chinese city where the first known cases were found—had insufficient access to adequately investigate possible sources of the new coronavirus, including whether it slipped from a laboratory.

. . .

WHO chief Tedros Adhanom Ghebreyesus said on Feb. 12 [2021] that the team would release an interim report briefly summarizing the Wuhan mission, possibly the following week, with a full report coming weeks later. But that summary report has yet to be published and the WHO team is now scrapping that plan, said Peter Ben Embarek, the food-safety scientist who led the team.

. . .

According to an advance copy of the open letter, the group of 26 scientists and other experts in areas including virology, zoology and microbiology said that it was “all but impossible” for the WHO team to conduct a full investigation, and that any report was likely to involve political compromises as it had to be approved by the Chinese side.

A credible investigation required, among other things, confidential interviews and fuller access to hospital records of confirmed and potential Chinese coronavirus cases in late 2019, when the outbreak was first identified in Wuhan, said the letter signed by experts from France, the U.S., India, Australia and other countries.

Investigators should also be allowed to view records including maintenance, personnel, animal breeding and experiment logs from all laboratories working with coronaviruses, the letter said.

“We cannot afford an investigation into the origins of the pandemic that is anything less than absolutely thorough and credible,” the letter said. “Efforts to date do not constitute a thorough, credible, and transparent investigation.”

The appeal is unlikely to gain traction, as any future probes would require Beijing’s cooperation. Moreover, many leading infectious-disease experts are skeptical that a lab accident could plausibly explain the origins of the pandemic.

Still, it expresses what has become a more widely shared dissatisfaction, voiced by the U.S. and U.K. governments and many scientists world-wide, that China has provided too little information and data to the WHO to guide researchers trying to determine where the virus originated and how it jumped to humans.

. . .

A laboratory accident is “definitely not off the table,” Dr. Ben Embarek told a seminar last week. Dr. Tedros said in February after the team’s trip that “all hypotheses remain open and require further analysis.”

The signatories of the open letter are mostly members of a broader group, spearheaded by French scientists, who have been sharing research papers and other information on Covid-19 since around December. None are associated with the WHO investigation.

Among the signatories are Etienne Decroly and Bruno Canard, molecular virologists at AFMB Lab, which belongs to Aix-Marseille University and the French National Centre for Scientific Research, France’s state research agency.

Dr. Decroly said he became involved after concluding that on the basis of available data, it was impossible to determine whether SARS-CoV-2 “is the result of a zoonosis from a wild viral strain or an accidental escape of experimental strains.”

The letter was co-organized by Gilles Demaneuf, a French data scientist based in New Zealand, and Jamie Metzl, a U.S.-based senior fellow for the Atlantic Council and adviser to the WHO on human genome editing.

Prominent critics of the laboratory hypothesis have in recent weeks published new research on bat coronaviruses found in Southeast Asia and Japan that they say shows that SARS-CoV-2 most likely evolved naturally to infect humans.

Robert Garry, a virologist at the Tulane University School of Medicine who was involved in that research, said he and other colleagues had initially considered the possibility of a leak or accident from a laboratory, but ultimately deemed it “nearly impossible.”

The Biden administration hasn’t publicly repeated its predecessor’s specific assertions regarding Wuhan laboratories.

Signatories of the open letter say they don’t back any one hypothesis but think it is premature to exclude the possibility of a leak or accident at or connected with a research facility such as the Wuhan Institute of Virology, or WIV, which runs high-security laboratories and has conducted extensive research on bat coronaviruses.

WIV scientists deny the virus came from there, saying they neither stored nor worked on SARS-CoV-2 before the pandemic and none of their staff tested positive for the virus.

Signatories said investigators should look at several possible scenarios, including whether a laboratory employee became infected with a naturally evolving virus while sampling bats in the wild, during transport of infected animals, or during disposal of lab waste.

They also said investigators should probe whether SARS-CoV-2 could have stemmed from “gain-of-function” experiments, in which viruses found in the wild are genetically manipulated to see if they can become more infectious or deadly to humans.

For the full story, see:

Betsy McKay, Drew Hinshaw, and Jeremy Page. “WHO Delays Release of Virus Origin Report.” The Wall Street Journal (Friday, March 5, 2021): A8.

(Note: ellipses, and bracketed dates, added.)

(Note: the online version of the story was updated March 5, 2021, and has the title “WHO Investigators to Scrap Plans for Interim Report on Probe of Covid-19 Origins.” The online edition says that the title in the print edition was “WHO Team Delays Release of Report on Virus’s Origin.” But my copy of the print edition had the title “WHO Delays Release of Virus Origin Report.”
The last 11 paragraphs quoted above appear in the online version, but not the print version, of the article.)

The open letter mentioned above, signed by 26 scientists from Australia, Austria, Belgium, France, Germany, India, New Zealand, Spain, the United Kingdom, and the United States, is:

Butler, Colin D., Bruno Canard, Henri Cap, Y. A. Chan, Jean-Michel Claverie, Fabien Colombo, Virginie Courtier, Francisco A. de Ribera, Etienne Decroly, Rodolphe de Maistre, Gilles Demaneuf, Richard H. Ebright, André Goffinet, François Graner, José Halloy, Milton Leitenberg, Filippa Lentzos, Rosemary McFarlane, Jamie Metzl, Dominique Morello, Nikolai Petrovsky, Steven Quay, Monali C. Rahalkar, Rossana Segreto, Günter Theißen, and Jacques van Helden. “Open Letter: Call for a Full and Unrestricted International Forensic Investigation into the Origins of Covid-19.” March 4, 2021.

Successful Chinese Entrepreneur Stands Trial for Defending Free Speech

(p. A10) Like many entrepreneurs in China, Geng Xiaonan found a space in which to make a small fortune — in her case, publishing books on cooking, health and lifestyle.

But unlike many Chinese entrepreneurs, she mixed with critics of the party, organizing dinners and salons that brought together liberal intellectuals, retired officials and longtime dissenters.

Now, Ms. Geng is set to stand trial in Beijing on Tuesday [Feb. 9, 2021] and may spend years in prison for her support for those at odds with China’s deepening authoritarianism, her supporters say. She and her husband, Qin Zhen, have been charged with illegal business activities related to their publishing company. Friends and sympathetic legal experts maintain that her real offense in the eyes of the government was straying from business into sympathizing with critics of Communist Party power.

Ms. Geng, 46, came under growing surveillance last year after she leapt to the defense of Xu Zhangrun, a law professor in Beijing who was suspended after publishing essays scathingly critical of the party and its top leader, Xi Jinping.

“This is simply political persecution,” said Cai Xia, a former professor at the Central Party School in Beijing, who said she had been friends with Ms. Geng for about eight years. Ms. Cai has moved to the United States, where she has denounced the Chinese Communist Party’s tightening of political controls.

“It’s a selective system of enforcement,” Ms. Cai added. “They can make up whatever they want when they want to slap a crime on you.”

Ms. Geng is the latest among a handful of Chinese entrepreneurs detained or imprisoned since last year as the party draws a harder line on businesspeople it deems challengers of Beijing’s rule.

For the full story, see:

Chris Buckley. “Chinese Entrepreneur Was Model of Success, Then She Got Too Close to Critics of the Party.” The New York Times (Tues., February 9, 2021): A10.

(Note: bracketed date added.)

(Note: the online version of the story has the date Feb. 8, 2021, and has the title “This Chinese Businesswoman Was a Model of Success. Then She Angered the Party.”)